PT - JOURNAL ARTICLE AU - Dipender Gill AU - Verena Zuber AU - Jesse Dawson AU - Jonathan Pearson-Stuttard AU - Alice R. Carter AU - Eleanor Sanderson AU - Ville Karhunen AU - Michael G. Levin AU - Robyn E. Wootton AU - VA Million Veteran Program AU - Derek Klarin AU - Philip S. Tsao AU - Konstantinos K. Tsilidis AU - Scott M. Damrauer AU - Stephen Burgess AU - Paul Elliott TI - Risk factors mediating the effect of body-mass index and waist-to-hip ratio on cardiovascular outcomes: Mendelian randomization analysis AID - 10.1101/2020.07.15.20154096 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.15.20154096 4099 - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154096.short 4100 - http://medrxiv.org/content/early/2020/07/16/2020.07.15.20154096.full AB - Background Higher body-mass index (BMI) and waist-to-hip ratio (WHR) increase the risk of cardiovascular disease, but the extent to which this is mediated by blood pressure, diabetes, lipid traits and smoking is not fully understood.Methods Using consortia and UK Biobank genetic association summary data from 140,595 to 898,130 participants predominantly of European ancestry, MR mediation analysis was performed to investigate the degree to which genetically predicted systolic blood pressure (SBP), diabetes, lipid traits and smoking mediated an effect of genetically predicted BMI and WHR on risk of coronary artery disease (CAD), peripheral artery disease (PAD) and stroke.Results The 49% (95% confidence interval [CI] 39%-60%) increased risk of CAD conferred per 1-standard deviation increase in genetically predicted BMI attenuated to 34% (95% CI 24%-45%) after adjusting for genetically predicted SBP, to 27% (95% CI 17%-37%) after adjusting for genetically predicted diabetes, to 47% (95% CI 36%-59%) after adjusting for genetically predicted lipids, and to 46% (95% CI 34%-58%) after adjusting for genetically predicted smoking. Adjusting for all the mediators together, the increased risk attenuated to 14% (95% CI 4%-26%). A similar pattern of attenuation was observed when considering genetically predicted WHR as the exposure, and PAD or stroke as the outcomes.Conclusions Measures to reduce obesity will lower risk of cardiovascular disease primarily by impacting on downstream metabolic risk factors, particularly diabetes and hypertension. Reduction of obesity prevalence alongside control and management of its mediators is likely to be most effective for minimizing the burden of obesity.Competing Interest StatementDG is a part-time employee of Novo Nordisk. JP-S reports personal fees from Novo Nordisk related to consultancy outside of the submitted work. All other authors have no conflicts of interest to declare.Funding StatementThis work was supported by funding from the US Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grant MVP003 (I01-BX003362). This publication does not represent the views of the Department of Veterans Affairs of the US Government. The MEGASTROKE project received funding from sources specified at http://www.megastroke.org/acknowledgments.html. Details of all MEGASTROKE authors are available at http://www.megastroke.org/authors.html. This work was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the University Hospitals Bristol National Health Service (NHS) Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. DG and JP-S are funded by the Wellcome 4i Clinical PhD Program at Imperial College London (203928/Z/16/Z). ARC and ES are funded by and work in a unit that receives core funding from the Medical Research Council (MRC) and University of Bristol (MC_UU00011/1). VK is funded by the European Unions Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). REW is a member of the MRC Integrative Epidemiology Unit at the University of Bristol funded by the MRC (MC_UU_00011/7). SMD was supported by the Department of Veterans Affairs Office of Research and Development (IK2-CX001780). SB is supported by Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). PE acknowledges support from the MRC (MR/S019669/1), the NIHR Imperial Biomedical Research Centre, Imperial College London (RDF03), the UK Dementia Research Institute (DRI) at Imperial College London funded by UK DRI Ltd (funded by MRC, Alzheimers Society, Alzheimers Research UK), and Health Data Research (HDR) UK London funded by HDR UK Ltd (funded by a consortium led by the MRC 1004231). The funding sources for this work were not involved in study design, data analysis, interpretation of results or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data used in this work are publicly available and the studies from which they were obtained are cited. All these studies obtained relevant participant consent and ethical approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results from the analyses performed in this work are presented in the main manuscript or its supplementary files.